Rischin, D., Porceddu, S. V., Day, F., Brungs, D., Christie, H. R., Jackson, J. E., Stein, B. N., Lim, A. M. L., Su, Y., Bowyer, S., Yamazaki, N., Bossi, P., Challapalli, A., Ladwa, R., Hauschild, A., McIntyre, D. A., Seebach, F. A., Yoo, S., Goncalves, P. H., Fury, M. G. (2026). C-POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma (CSCC): Disease-free survival (DFS) analyses per high-risk criteria and per start time after radiotherapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.6083